Introduction
Atrial fibrillation (AF) represents the most common rhythm disorder with a life-time risk for those reaching 40 years of age of 25% in Europe and the USA. 1 This arrhythmia is associated with a 2-fold increase in risk for death, due to a substantially increased risk for stroke. 1 Atrial fibrosis contributes to the pathogenesis of AF, as it interferes with electrical conduction by disrupting cardiomyocyte coupling. 2 Atrial fibrotic remodelling is a consequence of impaired extracellular matrix (ECM) turnover due to excessive deposition of collagen. Myofibroblast differentiation from cardiac fibroblasts, a consequence of the pro-fibrotic and pro-inflammatory reactions induced by transforming growth factor-b (TGF-b) and angiotensin II (AngII), leads to collagen accumulation, elevated rates of production of reactive oxygen species, and left atrial remodelling. 3 Nitro-fatty acids (NO 2 -FA) are electrophilic signalling mediators, which are generated by the reaction of nitrogen dioxide with unsaturated fatty acids, a reaction orders of magnitude more facile than nitration of tyrosine. 4 NO 2 -FA are detected in species ranging from plants to humans and are generated by nitrogen dioxide arising from both oxidative inflammatory and metabolic reactions dependent on nitric oxide and nitrite. NO 2 -FA and other 'soft' lipid electrophiles reversibly react via Michael addition with nucleophilic residues such as the hyperreactive cysteines of proteins. 5 NO 2 -FA mediate anti-inflammatory signalling actions via the modulation of signalling pathways including nuclear factor erythroid 2-related factor 2/kelch-like ECH-associated protein 1 (Nrf2/Keap-1)-regulated heme oxygenase 1 (HO-1) expression, nuclear factor kappa light chain enhancer of activated B cells (NF-kB) and mitogen-activated protein kinase (MAP kinase). 6 Recent studies have shown that dietary interventions can increase endogenous levels of these compounds, 7 and USFDA-approved Phase 1 safety and efficacy studies for synthetic NO 2 -FA are underway. Given the prominent role of inflammation in the pathogenesis of AF and atrial fibrosis, we evaluated whether an exemplary NO 2 -FA, nitro-oleic acid (OA-NO 2 ), suppresses development of atrial fibrosis and vulnerability to AF in a murine model of AngII-induced AF.
Methods

Animal model and handling
Wild-type C57BL/6J mice were treated for 2 weeks with AngII (1.5 ng/g/ min, Sigma-Aldrich, St Louis, USA) and nitro-oleic acid (6 mg/kg) solvated in polyethylene glycol/ethanol (90 : 10, vol/vol) or vehicle (polyethylene glycol/ethanol, 90 : 10), via subcutaneous implantation of osmotic minipumps (ALZET, Cupertino, CA, USA). Nitro-oleic acid (OA-NO 2 ) was provided from the lab of Bruce Freeman, PhD, University of Pittsburgh.
Animal groups:
Mice without AngII and OA-NO 2 -AngII(2)/OA-NO 2 (2) group Mice with AngII and without OA-NO 2 -AngII(+)/OA-NO 2 (2) group Mice with AngII and with OA-NO 2 -AngII(+)/OA-NO 2 (+) group
All animal procedures were performed with isofloran anaesthesia and analgesia with buprenorphine. Euthanasia was performed by heart excision in deep anaesthesia. All animal studies were approved by the local authorities (Behö rde für Soziales, Familie, Gesundheit und Verbraucherschutz, Fachabteilung Veterinärwesen und Lebensmittelsicherheit, Hamburg,G09/ 064 and Landesamt für Natur, Umwelt und Verbraucherschutz NordrheinWestfalen, 84-02.04.2012.A307) and by the Universities of Hamburg and Cologne Animal Care and Use Committees. Animal experiments conform to the guidelines from Directive 2010/63/EU of the European Parliament on the protection of animals used for scientific purposes. Observers were blinded for all quantitative analyses.
Electrophysiological investigation
Invasive right atrial stimulation was performed as described previously. 8 In brief, an octapolar electrophysiological catheter (1.1 F, Scisense, London, Canada) was inserted via the right jugular vein to the right atrium and ventricle. Intracardiac atrial and ventricular recording and atrial stimulation manoeuvres were performed using a CardioTek EPTracer (Biotronik, Berlin, Germany). Bipolar electrograms were obtained from each electrode pair during the whole procedure. Programmed atrial stimulation was performed at pacing stimulus amplitudes of 1.0 and 2.0 mA with 7 stimuli fixed rate at S1S1 cycle length of 120, 110, and 100 ms, respectively, with one short coupled extra stimulus with a 10 ms stepwise S1S2 reduction starting at cycle length of 80 ms down to 10 ms. Atrial burst stimulation was performed for 1 s (three times consecutively) at S1S1 stimulation cycle lengths starting at 50 ms with 10 ms stepwise reduction down to 10 ms at pacing stimulus amplitudes of 1.0 and 2.0 mA. Between these stimulation procedures, a 10 s recovery period was maintained. AF was defined by the presence of rapid and fragmented atrial electrograms in combination with irregular AV-nodal conduction and ventricular rhythm with a duration of these atrial electrograms of .1 s. The number of AF episodes and AF duration (last stimulus-spike to the first sinus-rhythm P wave) was analysed.
Ex vivo electrophysiological atrial mapping
For atrial electrophysiological mapping, hearts of mice were excorporated and cannulized with a blunted canula, connected to a Langendorff system, and retrogradely perfused via the aorta and the coronary arteries with a carbogen gas flushed Krebs Henseleit buffer with a constant flow of 1.5 mL/min. A 32-electrode microelectrode array (MEA, Multichannel Systems, Reutlingen, Germany) was positioned on the epicardial surface of the right atrium. Electrograms were recorded using a 128-channel, computerassisted recording system (Multichannel Systems) with a sampling rate of 25 kHz (25 000 samples/s). Data were bandpass filtered (50 Hz), digitized with 12 bits and a signal range of 20 mV. Activation maps were calculated from these data using custom-programmed software (Excel, Microsoft, Redmond, WA, USA). The first derivative of each unipolar electrogram was evaluated, and the minimum of dV/dt activation was defined as time point of local activation for pacing studies. To obtain an index of local conduction slowing for each electrode, the activation time differences to neighbouring points were normalized to inter-electrode distance (300 mm). The largest difference at each site is defined as local phase delay. The average phase delay and the absolute inhomogeneity of phase delays were calculated and used as index for smoothness in global conduction. For pacing studies, the hearts were stimulated with a concentric bipolar electrode (FHC, Bowdoin, USA) with a stimuli rate of 7 Hz at the aortic root. 
Patch clamp technique
Masson's trichrome and Picrosirius red staining of atrial sections
Amount of atrial fibrosis was determined by performing both Picrosirius red and Masson's trichrome staining. Paraffin-fixed atrial sections were stained with either Picrosirius red or Goldner Solutions I -III (Carl Roth GmbH, Germany), respectively. Planimetry was performed with IVision software (BioVision Technologies, Exton, PA, USA).
Cell culture
The murine RAW 264.7 macrophages and NIH/3T3 fibroblasts (ATCC, Manassas, VA, USA) were seeded to 6-well plates and left to adhere in DMEM (PAN-Biotech, Aidenbach, Germany) supplemented with 10% of fetal bovine serum (FBS, low endotoxin; PAA, Pasching, Austria) and 1% gentamycin. Immediately before the start of experiments, the complete DMEM medium was replaced by FBS-free DMEM, and cells were cultivated with OA-NO 2 (0.1 -1 mM) for harvest at different time points, as indicated in Results section.
Nitro-fatty acids in atrial fibrillation
RAW 264.7 macrophage and fibroblast ROS generation
Chemiluminescence (CL) was measured using a microplate luminometer LM-01T (Immunotech, Prague, Czech Republic). Briefly, macrophages cultivated in FBS-free DMEM medium were activated with phorbol-12-myristate-13-acetate (PMA) at 97.6 mg/mL in the presence of 1 mM luminol. The CL emission representing the oxidative burst was monitored for 4 h at 378C, and the integral value of the CL reaction was recorded. Recognizing that luminol chemiluminescence has limitations in the measurement of reactive species, an alternative strategy was also used for detection of rates of reactive oxygen species (ROS) production by macrophages. 9 The extracellular production of superoxide anion by RAW 264.7 macrophages and 3T3 fibroblasts was determined using spectrophotometric analysis of cytochrome c reduction (final concentration 100 mM). The reduction of cytochrome c was monitored at 550 nm, and the difference in absorbance between individual time points was converted to equivalent O − 2 production using the molar extinction coefficient for cytochrome c (21.1 mM 21 cm
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).
IF of a-smooth muscle actin and connexin 43
Hearts were frozen in OCT compound and cut to 4 mm longitudinal sections. Sections were thawed, were fixed with 3.7% formaldehyde solution, and were blocked with 10% mouse serum. Slides were treated with 0.1% Triton X-100 and incubated either with primary antibody against a-smooth muscle actin (a-SMA; 1 : 200, rabbit IgG, ab5694, Abcam, Cambridge, UK) and DDR-2 (1 : 50, goat IgG, sc7555, Santa Cruz, TX, USA) or with primary antibody against connexin 43 (Cx43; 1 : 1000, rabbit IgG, C6219-2 ML, Sigma-Aldrich, USA) and N-cadherin (1 : 1000, rabbit IgG, sc-1502, Santa Cruz, USA) for 1 h at RT in PBS with 0.1% Triton-X100 and 10% mouse serum. Secondary antibody was Alexa Fluor-594 chicken anti-rabbit IgG and Alexa Fluor-488 chicken anti-goat IgG (Invitrogen) and nuclei were stained with DAPI. Images were taken with a Retiga 1300 CCD camera mounted on Leica DMLB fluorescence microscope by iVision v4.0. For imunostaining of NIH/3T3 fibroblasts, BD Falcon CultureSlides were used. Cells were fixed with 4% formaldehyde, permeabilized using 0.1% Triton X-100, and blocked with 10% goat serum. Primary antibody against a-SMA (1 : 100, mouse IgG; Biomeda V1031), goat anti-mouse IgG (H + L) secondary antibody, DyLight 488 conjugate (Thermo Scientific) were used. Nuclei were stained with DAPI. Images were taken with a Retiga 1300 CCD camera mounted on Leica DMLB fluorescence microscope by iVision v4.0. Quantification of myofibroblasts was performed by counting a-SMA/ DDR2-positive cells in atrial sections. The observer was blinded during the quantification.
Dihydroethidium staining of atrial sections
Frozen atrial sections were stained with dihydroethidium (DHE, 5 mM, diluted in DMSO and HBSS buffer) as another index of oxidant generation. 10 The slides were incubated with DHE for 30 min at 378C in the dark before pictures were taken with a fluorescence microscope (DMLB, Leica, Solms, Germany) and planimetrically quantificated by using IVision software (BioVision Technologies, Exton, PA, USA).
Detection of protein expression by western blot analysis
Equal amounts of protein (20 mg) from each cell lysate were subjected to SDS -PAGE. The protein was then transferred to polyvinylidene difluoride (PVDF) membranes (Immobilon-P, Millipore, Billerica, MA, USA) and incubated with antibodies against a-smooth muscle actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), p38 MAPK, phospho-p38 MAPK (Thr180/ Tyr182), Smad2, and phospho-Smad2 (Ser 465/467) (all purchased from Cell Signaling Technology, Danvers, MA, USA). Membranes were further incubated with secondary antibodies conjugated with horseradish peroxidase. The blots were visualized using SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA) and exposed to CP-B X-ray films (Agfa, Brno, Czech Republic). The relative levels of proteins were quantified by scanning densitometry using the ImageJ TM program (National Institutes of Health, Bethesda, MD, USA), with the individual band density value expressed in arbitrary units (optical density, OD). Equal protein loading was verified by b-actin or a-tubulin immunoblotting (Santa Cruz Biotechnology).
Statistical analysis
One-way ANOVA test, followed by Fisher's least significant difference (LSD) post hoc test was used for comparison of treatment groups. Alternatively, Student's t-test was used as appropriate for comparisons between treatment groups. In the figures, statistical significance is mentioned with the asterisks *, **, and *** standing for a P-value of 0.05, 0.01, and 0.001, respectively. Results are expressed as mean values + SEM. Data were analysed with SPSS statistical software (IBM, Cologne, Germany) or Prism (Graphpad, La Jolla, CA).
Results
3.1 OA-NO 2 reduces the vulnerability for AF in AngII-treated mice After 2 weeks of continuous AngII administration, the number of AF episodes as well as the total time of episodes upon electrophysiological stimulation was markedly increased in AngII(+)/OA-NO 2 (2) mice compared with AngII(2)/OA-NO 2 (2) mice ( Figure 1A -C ) . Treatment with OA-NO 2 reduced AF vulnerability in AngII(+)/OA-NO 2 (+) mice with reductions in both number and total time of AF episodes to the level of AngII-naive animals ( Figure 1B and C ) . To control for direct interference of OA-NO 2 with Ang II release from the osmotic minipumps, Ang II plasma levels were measured after 2 weeks. AngII plasma levels were significantly higher in both AngII(+)/OA-NO 2 (2) and AngII(+)/OA-NO 2 (+) mice compared with AngII (2) animals, whereas no significant difference was observed between AngII(+)/ OA-NO 2 (2) and AngII(+)/OA-NO 2 (+) mice (see Supplementary material online, Figure S1 ).
OA-NO 2 suppresses atrial fibrosis and preserves atrial conduction homogeneity
Fibrosis is an established substrate of AF. A trichrome staining of paraffin-embedded murine atrial sections revealed significantly greater atrial fibrosis in AngII(+)/OA-NO 2 (2) mice compared with AngII(2)/ OA-NO 2 (2) animals ( Figure 2A) . Compared with AngII(+)/ OA-NO 2 (2) mice, AngII(+)/OA-NO 2 (+) mice exhibited significantly reduced levels of atrial fibrosis, which were in fact equivalent to those of AngII-naive animals ( Figure 2B ). These findings corresponded to changes in conduction properties assessed by epicardial mapping ( Figure 2C) . Thus, absolute inhomogeneity and mean latency were significantly increased in AngII(+)/OA-NO 2 (2) mice compared with AngII(2)/OA-NO 2 (2) animals, whereas this effect of Ang II was completely abolished in AngII(+)/OA-NO 2 (+) mice ( Figure 2D and E) . Of note, absolute inhomogeneity showed a significant correlation with the amount of collagen deposition determined by trichrome staining (Pearson's r: 0.643, P ¼ 0.01). Furthermore, a Picrosirius red staining of another cohort of animals confirmed the results of the trichrome staining ( Figure 2F and G) .
Effect of OA-NO 2 on cardiomyocyte AP and Cx43
Assessment of key parameters of cellular electrophysiology (resting membrane potential, AP overshoot, and duration) of left ventricular cardiomyocytes was unaffected by OA-NO 2 (see Supplementary material online, Figure S2A-C) . Also no effect of OA-NO 2 on the expression and distribution of Cx43, which has been shown to critically contribute to cardiomyocyte coupling in the context of AF, could be observed (see Supplementary material online, Figure S2D and E).
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OA-NO 2 inhibits fibroblast transdifferentiation to myofibroblasts by inhibition of Smad2 activation
Co-staining of atrial tissue with DDR2 (tyrosine kinase receptor for fibrillar collagen) and a-SMA (marker of myofibroblasts) revealed a significant increase in myofibroblasts in AngII(+)/OA-NO 2 (2) compared with AngII(2)/OA-NO 2 (2) animals. In AngII(+)/OA-NO 2 (+), this effect was almost completely blunted ( Figure 3A and B) . In accordance, TGF-b-induced differentiation of 3T3 fibroblasts to myofibroblasts was significantly reduced by incubation of the cells with 1 mM OA-NO 2 as indicated by a-SMA expression in western blot analysis and immunofluorescent staining ( Figure 3C and D) . These findings were corroborated by a-SMA expression analysis of isolated murine cardiac fibroblasts, which revealed a significant OA-NO 2 -dependent reduction of a-SMA expression in these cells (see Supplementary material online, Figure S3 ). Moreover, TGF-b induced activation of Smad2 in 3T3 fibroblasts was significantly attenuated by OA-NO 2 (1 mM), as indicated by western blot analysis of Smad2 phosphorylation (Ser 465/467, Figure 3E ).
OA-NO 2 reduces atrial oxidative inflammatory mediator generation
To further substantiate the observed effects of OA-NO 2 , we investigated its effect on atrial oxidant formation as a contributing factor to atrial fibrotic remodelling and arrhythmogenicity. There was a significant reduction in DHE oxidation by atrial tissues in AngII(+)/ OA-NO 2 (+) animals compared with AngII(+)/OA-NO 2 (2) animals, which tended to be suppressed even more than in AngII-naive animals ( Figure 4A and B) . In accordance, there was an OA-NO 2 -mediated decrease in superoxide production by fibroblasts and macrophages ( Figure 4C -E) . Using murine peritoneal RAW 264.7 macrophages, there was a dose-dependent reduction of both NOX2 and its cytosolic regulatory protein p67phox expression as a key mechanism accounting for decreased ROS production by OA-NO 2 ( Figure 4F and G) . In addition, NOX2 staining of paraffin-embedded atrial sections revealed a significant higher amount of NOX2-positive cells in AngII(+)/ OA-NO 2 (2) animals, which was significantly reduced following OA-NO 2 administration ( Figure 4H and I) . Western blot analyses furthermore revealed a decreased phosphorylation of p38 MAP kinase. (Figure 4J) . Of interest, a significantly higher amount of M1 polarized macrophages in atria of AngII(+)/OA-NO 2 (2) animals assessed by a CD86 immunohistology was not influenced by an additional OA-NO 2 treatment ( Figure 5A and B) .
Discussion
Herein it is shown that in vivo NO 2 -FA administration potently reduced atrial fibrotic remodelling as well as susceptibility to AF and conduction inhomogeneity in AngII-pretreated mice. These anti-fibrotic effects of NO 2 -FA were mediated by Smad2-related suppression of myofibroblast differentiation, as well as inhibition of atrial generation of oxidative inflammatory mediators ( Figure 6 ).
Atrial fibrosis is a significant pathophysiological factor, which has been postulated to underlie most forms of AF.
2 It has been documented in patients with structural heart disease 14 and patients with lone AF, 15 correlating with AF persistence. 16 Mechanistically, atrial fibrosis disrupts cell -cell coupling between cardiomyocytes, thereby not only provoking inhomogeneities of electrical conduction (which favour re-entrant circuits 17 ) but also facilitating ectopic activity due to early and delayed after-depolarizations. 18 AngII is a central signalling mediator in the pathogenesis of atrial fibrosis, with AngII expression increased in patients with AF. 19 Moreover, rapid atrial pacing leads to secretion of AngII 20 and cardiac overexpression of angiotensin-converting enzyme leads to atrial fibrosis and AF. 21 In our AngII-dependent murine model of AF, OA-NO 2 completely abolished the pro-fibrotic effects of AngII treatment. Importantly, this inhibitory effect of OA-NO 2 on fibrotic remodelling is confirmed by two different quantitative stainings of atrial fibrosis derived from two independent sets of animals. Moreover, the relevance of atrial fibrosis on the observed susceptibility for AF is not only strongly supported by epicardial contact mapping studies showing complete reversal of the AngII-induced increase in latency and inhomogeneity of conduction by OA-NO 2 but also by the significant correlation observed between extent of atrial fibrosis assessed by trichrome staining and absolute inhomogeneity assessed by epicardial mappings performed in the same hearts. Mechanistically, myofibroblasts are a hallmark of pathological fibrotic remodelling of the myocardium. Their differentiation from fibroblasts, which is induced by haemodynamic, neurohumoral, and inflammatory mediators, is essential for stimulating extracellular collagen deposition and the increased arrhythmogenicity observed in this context. 22 There was a significant inhibition of both AngII-mediated myofibroblast formation and TGF-b-induced, Smad 2-dependent fibroblast differentiation by OA-NO 2 . In addition to being a key source of collagen during fibrotic remodelling, myofibroblasts also exert potent autocrine and paracrine actions, including secretion of TGF-b and even AngII and thus perpetuate a vicious circle leading to progressive atrial fibrosis. 22 The importance of interrupting this vicious circle by abrogating the formation of this cell type, as by OA-NO 2 -induced signalling responses, can thus not be overstated. Patient tissue studies reveal an association between oxidative protein modifications and AF. 23 These studies are flanked by more mechanistic studies in transgenic mice, pigs, and human tissue, which reveal a crucial role for oxidative inflammatory mediators in the pathobiology of AF. 3 In particular, a study using cardiac-specific Rac1-overexpression, a regulator of NADPH oxidase, showed increased atrial fibrosis due to NADPH oxidase-dependent superoxide production and reactions. 24 The present data reveal a markedly decreased formation of this and related reactive species in atrial tissue upon treatment with OA-NO 2 ( Figure 4B ). This finding is mirrored by a pronounced suppression of superoxide production by fibroblasts and macrophages. These two cell types are important sources of superoxide in AF, as fibroblasts are the most abundant cells in the heart and macrophages, which are recruited to atrial tissue as a consequence of AF, 25 are among the most highly active tissue sources of superoxide production. 26 The impact of OA-NO 2 on inhibiting oxidant generation formation is reinforced by the decreased expression of NOX2 assessed in atrial tissue and isolated macrophages, the NOX2 subunit p67phox, and the inhibition of p38 MAP kinase phosphorylation, a critical regulatory step in both NOX2 expression and its activation by phosphorylation. 27 Notably, NOX2 is a major superoxide and downstream oxidant source in multiple cell types, including macrophages and fibroblasts. 28 Import-
antly, previous studies have demonstrated that superoxide produced by activated macrophages is almost exclusively formed by NOX2, supporting 29 the fact that OA-NO 2 not only suppresses expression but also activity of NOX2. 30 This study used a murine model of AF induction by right atrial stimulation. Thus, a number of limitations may apply when trying to translate the present findings to human pathology. The mechanisms underlying AF in humans are complex and to date remain incompletely understood. Multiple theories have evolved from findings stemming from Figure 6 Proposed mechanism by which OA-NO 2 reduces fibrosis in the atrium of AngII-treated mice. OA-NO 2 decreases fibroblast transdifferentiation through inhibition of Smad-2 activation, as indicated by a reduction of a-SMA expression. Additionally, OA-NO 2 reduces atrial oxidative stress due to attenuation of superoxide production from macrophages and fibroblasts by inhibition of NOX2 and p67 phox expression via p38 MAPK deactivation. electrophysiological mapping studies, including the multiple wavelet and leading circle concept, but also more recent models suggesting spiral waves or rapidly firing ectopic foci evoked by early and delayed after-depolarizations. The mouse model used herein is not suitable to investigate these mechanisms. However, the main focus of this study was to assess the effect of OA-NO 2 on atrial fibrosis as a crucial substrate for most of the above-noted models of AF, for which murine models have been widely used. 21 The increased inducibility of AF demonstrated in this work underpins the relevance of the observed effects of OA-NO 2 on suppressing atrial fibrosis. Furthermore, it has to be noted that OA-NO 2 also inhibits angiotensin 1 receptor activation, 31 thus it cannot be ruled out that the observed in vivo effects of OA-NO 2 on AF and atrial fibrosis observed herein are partially related to inhibition of the angiotensin 1 receptor activation. However, our in vitro data showing OA-NO 2 -mediated reduction in TGF-b-induced myofibroblast transdifferentiation and inhibition of macrophage superoxide production reveal effects of OA-NO 2 beyond direct inhibition of AngII 1 receptor activation. These considerations are relevant, as they suggest a broader applicability of these results, which are not merely restricted to the AF model employed herein. They are also of relevance considering the fact that AngII inhibition in patients with AF yielded variable results.
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In conclusion, the nitro-fatty acid OA-NO 2 potently inhibits AngIIdependent atrial fibrosis and subsequent vulnerability to AF induction, by interfering with AngII-signalling on multiple levels. Nitro-fatty acids thus emerge as potential therapeutic agents for AF either by increasing endogenous levels through dietary interventions or as synthetic drugs.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
